Evogene Announces Acute Graft-Versus-Host Disease As Target Indication For Its Internal Drug Discovery Program
Benzinga Newsdesk 3 days ago
News
Advancing a First-in-Class Small-Molecule Therapeutic, Guided by World-Leading Experts, to Address a Multi-Billion-Dollar Unmet Need in Steroid-Refractory PatientsREHOVOT, Israel, Oct. 28, 2026 /PRNewswire/ -- Evogene
Advancing a First-in-Class Small-Molecule Therapeutic, Guided by World-Leading Experts, to Address a Multi-Billion-Dollar Unmet Need in Steroid-Refractory Patients
REHOVOT, Israel, Oct. 28, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules for the pharmaceutical and agricultural industries, today announced acute graft-versus-host disease (aGVHD) as the target indication for its internal drug discovery program.